All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Which factors influence the need for allo-SCT consolidation in patients treated with CAR T-cells?

During the 6th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2021), the ALL Hub was pleased to speak with Michael Pulsipher, Children's Hospital Los Angles, California, US. We asked, Which factors influence the need for allogeneic stem cell transplant consolidation in patients treated with chimeric antigen receptor (CAR) T-cells?

Which factors influence the need for allo-SCT consolidation in patients treated with CAR T-cells?

Pulsipher begins by discussing curative CAR T-cell products and key factors to consider in CAR T-cell selection. He goes on to outline risk factors for increased likelihood of failure such as B-cell aplasia or next generation sequencing based measurable residual disease. Finally he highlights his upcoming study (CAR Cure trial) where they will test the feasibility of moving patients to transplant regularly should they fall into the high risk category.

 

Share: